Extension Of Eliquis’ Indication Will See It Face Off Against Xarelto And Pradaxa In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe’s top drug regulator recommended an additional indication for Bristol-Myers Squibb/ Pfizer’s Eliquis for AF, setting the stage there for a showdown with Bayer/J&J’s Xarelto and Boehringer Ingelheim’s Pradaxa.
You may also be interested in...
Amended AMNOG Sees New Life Breathed Into Trajenta Reimbursement Bid In Germany
Changes to Germany’s drug reimbursement law have permitted Boehringer Ingelheim and Eli Lilly to submit an updated dossier for their oral therapy Trajenta, giving medicine makers who operate there hope that further positive amendments will occur.
Xarelto, Pradaxa Difficult To Separate After Positive NICE Final Guidance
Bayer’s Xarelto has made it into the NHS in England after its NICE recommendation went unchallenged, prompting a head to head battle with Boehringer Ingelheim’s Pradaxa.
European HTA: Cancer Drugs Suffer At NICE, Whilst IQWiG And HAS Also Tighten Purse Strings
Economic austerity and the resulting pressure on health care spend leaves little room for maneuver among Europe’s health technology assessment agencies.